Showing results (311-320 of 323) with videos related to
Sort By:
Pageof 33
European Journal of Medicinal Chemistry|May 2, 2021
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter sppJoel A Goldberg, Vijay Kumar, Elizabeth J Spencer, et al.Scientific Reports|February 27, 2021
Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumanniiJasmine Martinez, Chelsea Razo-Gutierrez, Casin Le, et al.Antimicrobial Agents and Chemotherapy|October 30, 2024
ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibutenMichael R Jacobs, Caryn E Good, Ayman M Abdelhamed, et al.Antimicrobial Agents and Chemotherapy|August 12, 2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.Mbio|March 14, 2019
Targeting Multidrug-Resistant <i>Acinetobacter</i> spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic AgentMelissa D Barnes, Vijay Kumar, Christopher R Bethel, et al.Journal of Medicinal Chemistry|April 10, 2018
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234Krisztina M Papp-Wallace, Nhu Q Nguyen, Michael R Jacobs, et al.United European Gastroenterology Journal|October 22, 2025
Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER)A Gerussi, E Nofit, D P Bernasconi, et al.Alimentary Pharmacology & Therapeutics|September 3, 2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's diseaseL S Kiss, T Szamosi, T Molnar, et al.Journal of Cachexia, Sarcopenia and Muscle|October 4, 2011
The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexiaR Dallmann, P Weyermann, C Anklin, et al.Archives of Disease in Childhood|December 14, 2020
Development of an international standard set of patient-centred outcome measures for overall paediatric health: a consensus processBeatrix Algurén, Jessily P Ramirez, Matthew Salt, et al.Pageof 33